As part of a multidisciplinary team which cares for patients age 65 and older, Dr. Hamlin has worked to develop new treatment strategies for older patients with lymphoma. He has developed new screening tools to identify patients at potentially increased risk for treatment side effects along with the development of clinical trials specifically aimed at addressing the needs of the older patient population. We have as our shared goal the development of effective risk-adapted therapies to minimize the side effects of treatments and maximize their effectiveness.
Dr. Hamlin received his medical degree from SUNY Downstate School of Medicine. He completed his Residency at the NYU (New York University) Medical Center and he is currently under Fellowship with the Memorial Sloan-Kettering Cancer Center in New York. Dr. Hamlin is board certified in Internal Medicine and Medical Oncology and his clinical expertise are Diffuse, Large B Cell Lymphoma in the Elderly, Radio-Immunotherapy, Non-Hodgkin Lymphoma, Hodgkin’s disease and Mantle Cell Lymphoma.
As a clinical researcher, I am exploring novel biologic and immunotherapeutic agents for the treatment of HD and NHL. My prior work focused on vaccine approaches for NHL and the use of radio immunotherapy, with ongoing efforts exploring novel antibody therapies and antibody-drug combinations.”
Dr. Paul A. Hamlin